BTIG analyst Mark Massaro raised the firm’s price target on Exact Sciences to $110 from $95 and keeps a Buy rating on the shares after its Analyst Day presentation where the company initiated a 2022-2027 revenue CAGR target of 15% and also unveiled strong improvement to Cologuard with its BLUE-C readout. The outlook is beatable and Exact Sciences’ growth drivers are durable as the company is only 10% penetrated with Cologuard, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on EXAS:
- Exact Sciences price target raised to $130 from $100 at Citi
- Exact Sciences price target raised to $120 from $92 at TD Cowen
- Exact Sciences price target raised to $96 from $81 at Benchmark
- Credit Suisse keeps Neutral on Exact after BLUE-C data readout for Cologuard 2.0
- Exact’s BLUE-C top-line data beat expectations, says William Blair